Adicet Bio, Inc. announced that updated safety and efficacy data from the Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphoma (NHL) will be delivered as an oral presentation at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and online June 3-7, 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.495 USD | +9.93% | +3.10% | -20.90% |
03:57pm | Adicet Bio Says US FDA Grants Fast Track Designation for ADI-001 to Treat Lupus Nephritis | MT |
01:00pm | Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.90% | 112M | |
+52.29% | 55.7B | |
+41.08% | 39.91B | |
-5.78% | 39.57B | |
-5.56% | 28.16B | |
+16.22% | 26.3B | |
-20.04% | 18.94B | |
+32.49% | 12.17B | |
+26.45% | 12.12B | |
+1.83% | 12.12B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting